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Abstract
Fragile X syndrome (FXS) is mostly caused by a CGG triplet expan-
sion in the fragile X mental retardation 1 gene (FMR1). Up to 60%
of affected males fulfill criteria for autism spectrum disorder (ASD),
making FXS the most frequent monogenetic cause of syndromic
ASD. It is unknown, however, whether normal variants (indepen-
dent of mutations) in the fragile X gene family (FMR1, FXR1, FXR2)
and in FMR2 modulate autistic features. Here, we report an accu-
mulation model of 8 SNPs in these genes, associated with autistic
traits in a discovery sample of male patients with schizophrenia
(N = 692) and three independent replicate samples: patients with
schizophrenia (N = 626), patients with other psychiatric diagnoses
(N = 111) and a general population sample (N = 2005). For first
mechanistic insight, we contrasted microRNA expression in peri-
pheral blood mononuclear cells of selected extreme group subjects
with high- versus low-risk constellation regarding the accumula-
tion model. Thereby, the brain-expressed miR-181 species emerged
as potential “umbrella regulator”, with several seed matches
across the fragile X gene family and FMR2. To conclude, normal
variation in these genes contributes to the continuum of autistic
phenotypes.
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Introduction
Fragile X syndrome (FXS) is associated with symptoms ranging from
learning, motor and emotional deficiencies to mental retardation
(IQ < 70) and autism (Garber et al, 2008). Up to 60% of males with
FXS fulfill criteria for autism spectrum disorder (ASD) (Hagerman
et al, 1986; Bailey et al, 1998; Clifford et al, 2007; Harris et al,
2008), making FXS the most common monogenetic cause of
syndromic ASD (Hagerman et al, 2011). Almost all individuals with
FXS show at least some autistic characteristics like social with-
drawal (Hatton et al, 2006; Dahlhaus & El-Husseini, 2010; Heitzer
et al, 2013). Since FXS is an X-linked disorder, males are generally
more severely affected, with a suggested prevalence in Caucasians
ranging from 1/3,717 to 1/8,918 (Crawford et al, 2001, 2002; Coffee
et al, 2009).
FXS is in most cases caused by a CGG triplet expansion in the
50-untranslated (UTR) region of the fragile X mental retardation 1
gene (FMR1). More than 200 repeat copies are considered a full
mutation, triggering hypermethylation of the CpG island in the
promoter region. This hypermethylation leads to transcriptional
silencing of FMR1 and loss of the associated protein, fragile X
mental retardation protein (FMRP) (Oberle et al, 1991; Pieretti et al,
1991; Verkerk et al, 1991). FMRP is an RNA-binding protein, abun-
dantly expressed in the mammalian brain, where it binds 4% of the
whole transcriptome, including its own message (Ashley et al,
1993). Since FMRP interacts with many other proteins, its absence
has manifold consequences—in sum affecting neural development,
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synapse formation, and plasticity (Bassell & Warren, 2008; Darnell
et al, 2011; Pasciuto & Bagni, 2014a). A premutation syndrome (55–
200 repeats) has also been reported with elevated FMR1 mRNA and
reduced FMRP levels, where RNA toxicity is a possible underlying
molecular mechanism (Garcia-Arocena & Hagerman, 2010; Bagni
et al, 2012). Premutation carriers display only subtle symptoms
which are, however, still reminiscent of FXS, including deficits in
social cognition, executive functioning, working memory, or
selective attention (Moore et al, 2004; Cornish et al, 2005, 2008;
Jacquemont et al, 2007; Kogan et al, 2008). Many of the FMRP
mRNA targets, for example CAMK2A, PSD-95, GABRB1, NLGN2,
have been linked to schizophrenia or ASD (Pasciuto & Bagni,
2014b). The most recent genomewide association study (GWAS) for
schizophrenia described an enrichment of FMRP targets among the
genomewide significant hits (Schizophrenia Working Group of the
PGC, 2014), and in the largest whole exome sequencing study for
schizophrenia, enhanced de novo mutations in mRNA targets of
FMRP were found (Fromer et al, 2014).
Two autosomal homologues of FMR1 exist—fragile X mental
retardation autosomal homolog 1 (FXR1) and 2 (FXR2)—together
forming the fragile X family of genes (Zhang et al, 1995). Both of
these homologues encode also for RNA-binding proteins, FXR1P
and FXR2P, respectively, with functions similar and complementary
to FMRP (Penagarikano et al, 2007; Ascano et al, 2012). For
instance, FMRP and FXR2P co-regulate crucial synaptic proteins like
PSD95 (Fernandez et al, 2015). Interestingly, genomewide signifi-
cant hits for schizophrenia also encompass the FXR1 locus
(Schizophrenia Working Group of the PGC, 2014).
Besides FXS, there is a phenotypically related unstable triplet
expansion disorder, associated with mild mental retardation, the
so-called fragile XE syndrome (Gecz, 2000). The mutation—similar
to FXS—is due to an expansion of a CCG repeat beyond 200 in the
50UTR of the AF4/FMR2 family member 2 (AFF2, also called FMR2),
which leads to hypermethylation of the CpG island upstream of
FMR2 and transcriptional gene silencing (Knight et al, 1993; Gecz
et al, 1996; Gu et al, 1996). FMR2 is a nuclear protein expressed
in fetal and adult brain and belongs to a gene family of transcription
activators (Gecz et al, 1997; Hillman & Gecz, 2001). Importantly,
an increased number of missense mutations in FMR2 was found
in male patients with ASD compared to controls (Mondal et al,
2012).
In summary, there seems to be a considerable connection of both
schizophrenia and ASD with the “broader fragile X family” of genes,
in which we have included FMR2 based on the striking functional/
phenotypical similarities and interactions. Along with the genetic
relationship between these mental disorders, clinical overlaps have
also been described, such as the shared impairment of specific
cognitive domains like theory of mind (King & Lord, 2011; Owen
et al, 2011).
Surprisingly, all that is known about genotype–phenotype associ-
ations in this broader fragile X gene family is derived from muta-
tions, but the contribution of common, frequent variations in these
genes to the normal continuum of autism-related phenotypes, for
example social interaction, communication, or stereotypies, has
never been investigated. In the present study, we asked for the first
time whether accumulated common genetic variants in genes of the
broader fragile X gene family (FMR1, FXR1, FXR2, FMR2) modulate
autistic features in males, independently of the described mutations,
that is, the polymorphic repeats in FMR1 and FMR2. For quan-
tification of autistic phenotypes, we used the PAUSS, an autism
severity score composed of specific items of the Positive and Nega-
tive Syndrome Scale (PANSS autism severity score) (Ka¨stner et al,
2015).
We report here an accumulation model of 8 single nucleotide
polymorphisms (SNPs) that yields significant association with
autistic traits in a schizophrenic discovery and two independent
replicate samples of mentally ill subjects, as well as one replicate
sample from the general population. In a first and still preliminary
approach toward mechanistic insight, we employed small RNA
sequencing and found lower expression of miR-181 species in
peripheral blood mononuclear cells (PBMC) of subjects with high-
versus low-risk constellation in the 8-SNP model. The fact that
this microRNA family has several seed matches across the broader
fragile X gene family may suggest an overarching regulatory
mechanism.
Results
Length distribution of FMR1 and FMR2 repeat polymorphisms in
the male schizophrenic discovery sample is indistinguishable
from healthy individuals
As prerequisite for exploring the contribution of normal variation in
genes of the broader fragile X gene family (FMR1, FXR1, FXR2,
FMR2) to the overall continuum of autism-related phenotypes, we
had to determine the polymorphic repeat lengths in FMR1 and FMR2
in the schizophrenic discovery and the healthy control sample to
exclude mutations. As illustrated in Fig 1, repeats were similarly
distributed in the Go¨ttingen Research Association for Schizophrenia
(GRAS) patients and healthy controls. All had < 50 CGG and < 40
CCG repeats in FMR1 and FMR2, respectively, that is, far away even
from premutation carrier status (Tassone et al, 2014). We then
checked whether the (normal) repeat length would still have any
relevance for schizophrenia symptom severity in the discovery
sample. As shown in Table 1, no associations were found with age
at disease onset, positive, cognitive, neurological symptoms or
PAUSS (Ka¨stner et al, 2015). Even comparing the top and bottom
10% of GRAS individuals with smallest or largest repeat lengths did
not result in any significant differences (Table 1).
An accumulation model of 8 proautistic genotypes of the broader
fragile X family predicts autistic phenotypes in the schizophrenia
discovery sample
Having a comparable basis of repeat polymorphism distribution in
the schizophrenia discovery sample with no obvious influence on
disease readouts, we first selected SNPs in the broader fragile X gene
family according to our standard operating procedure (SOP) as
meticulously described in Figs 2 and 3 and in the materials and
methods section. The high internal consistency of all individual
PAUSS items (Ka¨stner et al, 2015) allowed their aggregation to form
a single dimensional measure of the severity of autistic symptoms
(Fig 4A) and to explore the preselected 13 SNPs (Fig 2) individually
with respect to potential proautistic genotypes (SOP: Fig 3). Accord-
ing to this SOP, the following 8 proautistic genotypes out of the 13
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SNPs were chosen that revealed a tendency of a higher PAUSS (i.e.
higher severity of autistic symptoms): T in FMR1 rs25699, TT in
FXR1 rs6763069, AA in FXR1 rs2601, GG in FXR2 rs34416693, CC in
FXR2 rs62059833, A in FMR2 rs241084, G in FMR2 rs17318323, and
G in FMR2 rs6641482. These genotypes were used for generation of
the 8-SNP accumulation model.
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Figure 1. Positions of SNPs in FMR1, FXR1, FXR2, and FMR2, forming the 8-SNP model as well as FMR1 and FMR2 repeat polymorphism length distribution in
the discovery sample.
A Schematic overview of FMR1, FXR1, FXR2, FMR2, and position of the 8 selected single nucleotide polymorphisms (SNPs). Line represents introns, gray box at the
beginning and end of each gene stands for UTR region, and red boxes represent exons. Gene structure plots generated using FancyGene (Rambaldi & Ciccarelli, 2009).
B Distribution of repeat polymorphism lengths in FMR1 of male GRAS schizophrenia patients and healthy controls.
C Distribution of repeat polymorphism lengths in FMR2 of male GRAS schizophrenia patients and healthy controls.
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To exclude that any of the so-selected 8 SNPs would be
associated with the diagnosis of schizophrenia, we first conducted a
case–control analysis of the male GRAS schizophrenic and healthy
control subjects, yielding no statistically significant results. All
markers fulfill Hardy–Weinberg equilibrium after significance level
was corrected for multiple testing (P < 0.013) (Table 2). Hence, all
individuals of the discovery sample could now be ranked according
to their number of proautistic genotypes. In this sense, for the auto-
somal genes (FXR1, FXR2), homozygous proautistic genotypes were
always counted as 1; heterozygous proautistic genotypes as 0.5 and
the non-proautistic genotypes as 0. For the X-chromosomal genes
(FMR1, FMR2), the proautistic genotypes were counted as 1 and the
non-proautistic genotypes as 0 (Fig 3). Figure 4B displays the aver-
age PAUSS of all individuals in the discovery sample dependent on
the number of accumulated proautistic genotypes. Higher numbers
correlate with higher PAUSS (rs = 0.103, P = 0.008). In contrast,
these numbers do not correlate with unrelated control phenotypes,
for example, our delusional depression composite score (Fig 3C and
D).
When contrasting extreme group individuals, that is, those with
1.5–2.5 to those with 5.5–6.5 proautistic genotypes, a highly signifi-
cant difference (P = 0.0002) regarding severity of autistic features
emerged (Fig 4C). Table 3 highlights the overall contrast between
the two extreme groups with regard to autism-relevant measures,
that is, PAUSS and individual score items, with the most striking
group difference of all single items seen for social withdrawal. In
contrast, none of the control variables differs between the extreme
groups, including lengths of repeat polymorphisms, age, positive,
cognitive, or neurological symptom severity (Table 3).
As internal validity control of the 8-SNP model, an exploratory
exclusion of each SNP was performed to learn whether the signifi-
cance level of the model’s associations with PAUSS or its subitems
as presented in Table 3 would be affected. In all 8 of the so-created
7-SNP models, essentially all associations deteriorated, thus clearly
supporting the chosen 8-SNP model (Table 4).
The association of the 8-SNP model derived from the broader
fragile X gene family with autistic phenotypes is replicated in
three independent samples
To test whether the associations of the 8-SNP model with autistic
phenotypes found in the GRAS discovery sample were consistent,
we employed three independent replication samples: (I) male
patients with schizophrenia from Munich/Halle (N = 626), (II) male
patients with other psychiatric diagnoses (extended GRAS data
collection; N = 111), and (III) a general population sample of males
from Greifswald (N = 2,005). For replication samples I and II, the
PAUSS was employed, again resulting in clear differences between
extreme groups with low and high numbers of proautistic
genotypes, comparable to the discovery sample (Fig 4D and E). For
replication sample III, social support [derived from the Instrumental
Support Index (Klein et al, 2012)] was used as a proxy phenotype.
Reassuringly, in the discovery sample, social support (operational-
ized as the self-reported number of individuals a person can rely
on in case of emergency) correlated substantially with the
PAUSS (Spearman rank correlation for N = 639: rs = 0.313,
P = 5 × 1016, Fig 4F), underlining the relevance of this phenotype
for autism. For the PAUSS item social withdrawal, the correlation
was even more pronounced than for the overall PAUSS (Spearman
rank correlation for N = 649: rs = 0.337, P = 1.2 × 1018).
Extreme groups with low and high numbers of proautistic genotypes
diverged substantially regarding social support in the discovery
sample as well as replication sample III (Fig 4G and H). To
conclude, in all three replication samples, we confirmed the associa-
tion of the 8-SNP model, derived from the broader fragile X gene
family (FMR1, FXR1, FXR2, FMR2), with autism-related behaviors,
Table 1. Correlation of repeat length polymorphisms with measures of schizophrenia disease severity and autistic features in the male
schizophrenia GRAS sample and extreme group comparison of repeat length polymorphisms for the same measures.






























rs = 0.024 P = 0.540 24.75  7.95 24.25  7.25 Z = 0.36
P = 0.721




rs = 0.057 P = 0.149 14.24  5.70 13.20  5.62 Z = 1.11
P = 0.269





rs = 0.021 P = 0.595 0.07  1.12 0.07  0.97 t = 0.70
P = 0.484
0.035 P = 0.378 0.02  0.99 0.04  0.96 t = 0.08
P = 0.935
CNIb rs = 0.037 P = 0.362 0.02  0.89 0.03  0.95 Z = 0.34
P = 0.736
0.035 P = 0.400 0.05  0.84 0.04  0.91 Z = 0.69
P = 0.494
PAUSSc rs = 0.006 P = 0.870 0.03  0.67 0.05  0.75 Z = 0.53
P = 0.598
0.027 P = 0.499 0.06  0.64 0.03  0.61 Z = 0.67
P = 0.504
Uncorrected mean  SD presented. Spearman’s correlation coefficient (rs) was calculated for FMR1/FMR2 repeat polymorphisms and respective disease measures.
For further statistical analysis of extreme groups (10% with longest and 10% with shortest repeats), Mann–Whitney U-test or t-test for normally distributed
variables was used. PANSS, positive and negative syndrome scale; CNI, Cambridge neurological inventory.
aBecause of missing data, sample sizes vary.
bCorrected for age and chlorpromazine equivalents (standardized residual after linear regression).
cZ-standardized PANSS autism severity score.
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underlining the phenotypical continuum of these traits across health
and disease.
Autism-relevant 8-SNP model derived from the broader fragile X
gene family: Toward first mechanistic insight
Next, the obvious question arose of how to explain the role in aggre-
gate of variants within the broader fragile X gene family for the
development of autistic features. Interactions and/or partial compen-
sation/substitution of some of these genes for each other have
already been suggested [for example Ceman et al (1999), Jin et al
(2004), Fernandez et al (2015)]. In a preliminary approach toward
mechanistic insight, we chose the functionally interesting SNP
rs2601 A/G, located in the 30UTR of FXR1. In silico prediction using
PITA algorithm (Kertesz et al, 2007) revealed here an allele depen-
dent variable binding of miR-181 species in case of G versus A. For
the G allele, the ΔΔG prediction ranges from 3.84 to 9.90; for the
A allele, it is 0 (AA is the proautistic risk genotype in our model)
(Fig 5). Not only brain, but also thymus or PBMC express relatively
high amounts of miR-181 species (Hsu et al, 2006; Landgraf et al,
2007; Asquith et al, 2014). Therefore, we hypothesized that FXR1
mRNA expression in PBMC should be lower in GG carriers due to the
predicted strong binding of miR-181 species. Comparing FXR1
expression in subjects homozygous for rs2601 G (N = 16) versus A
(N = 27), we saw a tendency in the expected direction (Fig 5A).
We now wondered whether the other seven risk genotypes in
the model would contribute to alterations in the regulatory
microenvironment, for example, the microRNAome. For this, we
controlled for the effect of the rs2601 genotype by selecting only
AA carriers. We formed two extreme groups (N = 6 each), that
is, with 2–2.5 versus 5.5–6.5 proautistic genotypes now also
considering the remaining 7 SNPs. Contrasting microRNA expres-
sion in PBMC of these 2 extreme groups with high versus low
autism score/genetic risk, we found again miR-181 emerge. In
order to quantify all miR-181 molecules that target the broader
fragile X gene family, we performed small RNA sequencing and
saw that all miR-181 species (a, b, c, d-5p) together were lower
expressed in high-risk subjects (P = 0.024) (Fig 5B). We next had
a closer look at the miR-181 family members. Figure 5C illus-
trates the sequence homology of all four mature human miR-181
species and the remarkable number of miR-181 seed matches in
the broader fragile X gene family. Only in FXR2, no matching
sequence was found (Fig 5C). Figure 5D gives the predicted ΔΔG
for each of the miR-181 family members within different 30UTR
positions in the broader fragile X gene family. Positions were identified
using Target Scan Human (http://www.targetscan.org) and SFOLD
(http://sfold.wadsworth.org/cgi-bin/index.pl) and then processed
using PITA algorithm (Kertesz et al, 2007) to yield the denoted ΔΔG
values.
In contrast to the differentially expressed microRNAs in PBMC of
our extreme group subjects, FMRP levels were found to be similar
upon quantification by Western blot [1.5–2.5 (N = 6) versus 5.5–6.5
(N = 7) risk genotypes: 0.418  0.493 versus 0.522  0.651, rela-
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rs2601 (functional & MAF)
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2 MAF
5 LD
1 functional & MAF
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5 LD
2 MAF & LD 1 functional & MAF
3 functional & LD
1 functional
16 MAF & LD
97 MAF
16 LD
Figure 2. SNP overview and unbiased selection according to the standard operating procedure (SOP) developed for phenotype-based genetic association
study (PGAS) approaches.
A Genes from the “broader fragile X family” and their chromosomal position.
B SNP numbers available through direct genotyping in the here used semicustom genotyping array (Affymetrix, Santa Clara, CA, USA).
C SNPs fulfilling some of the first round of selection criteria (“functional” = SNPs, i.e. located in promoter region, 30UTR or coding sequence; MAF = MAF ≥ 0.2;
LD = SNPs that “survive” after linkage disequilibrium pruning: r² < 0.8). Underlined are the 13 SNPs selected for the PGAS approach using the PAUSS (selection
requirements: fulfilled 2 of the above criteria or were functional). Not more than 3 SNPs per gene are selected to avoid overrepresentation of one gene.
D SNPs with a tendency in PGAS (see Fig 3A) at single SNP basis went into the final accumulation model.
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Discussion
In the present study, we provide a model of 8 common genetic
variants in genes of the broader fragile X family that co-modulate
autistic traits in a discovery sample of male patients with
schizophrenia and in three independent replication samples,
comprising: (I) schizophrenic individuals, (II) other psychiatric diag-
noses, and (III) general population. This co-modulation is indepen-
dent of the known mutations, that is, FMR1 and FMR2 repeat
polymorphism lengths. Extreme groups carrying high versus low
numbers of the 8-SNP model of risk genotypes do not only differ
substantially regarding the severity of autistic phenotypes but
apparently also with respect to the microRNAome as determined in
PBMC.
We have termed the kind of approach taken here PGAS
(phenotype-based genetic association study) which allows elucidat-
ing the contribution of normal genetic variation to (disease) pheno-
types, and thereby ultimately aims at re-defining disease entities
based on biological grounds (Ehrenreich & Nave, 2014). The results
of the present PGAS nicely illustrate that common genetic variants
in aggregate can at least co-determine a psychiatric disease pheno-
type and that mutations may not necessarily be required in all cases.
In fact, non-syndromic ASD is estimated to be in 10–20% mono-
genic, that is, caused by a clear-cut genetic mutation (Geschwind,
2011). Most cases are etiologically unclear. Some of them could well
be derived from an unfortunate aggregation of normal genotypes as
shown here, possibly combined with environmental risk factors in
the sense of a second hit (Tordjman et al, 2014).
For quantification of autistic traits, we employed our novel,
easy-to-apply dimensional PANSS-based autism severity score
(PAUSS) which has previously been cross-validated with the
autism diagnostic observation schedule (ADOS), an established
autism-scoring instrument (Ka¨stner et al, 2015). Importantly, we
did not find the 8-SNP model to be associated with any other read-
out of schizophrenia disease severity or control phenotypes,
emphasizing its specific role for autistic traits. In particular, social
withdrawal seemed to be substantially influenced by the number
of proautistic genotypes in the broader fragile X gene family, an
observation in good agreement with the literature on autistic
features in fragile X (and related) gene mutation carriers, man and
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Figure 3. Criteria of final SNP selection in the phenotype-based genetic association study (PGAS) approach—Standard operating procedure (SOP).
A, B A total of 13 SNPs preselected according to the SOP presented in Fig 2 underwent PGAS screening as exemplified here: (A) PAUSS association pattern of an
exemplary fictitious autosomal (upper panel) and a sex-chromosomal (lower panel) SNP which are eligible for the accumulation model. The genotype associated
with the highest average PAUSS (in this example CC) is the “proautistic genotype” (indicated by the black arrow) and is assigned a score of 1. The heterozygous
genotype is assigned a score of 0.5 and the homozygous genotype associated with the lowest PAUSS receives a score of 0. Please note that the difference between
genotypes does not have to be statistically significant. (B) PAUSS association pattern of an exemplary fictitious autosomal (upper panel) and a sex-chromosomal
(lower panel) SNP which would not be selected for the accumulation model because of unclear phenotypical/biological relevance.
C, D The specificity of the association of the 8-SNP accumulation model with an autistic phenotype (as determined using PAUSS; compare Fig 4B) is controlled by
applying an unrelated (or “non-sense”) phenotype, for example, delusional-depression: (C) Intercorrelation pattern of single items included in the delusional-
depression composite score, used here as example control phenotype. Cronbach’s alpha is presented as measure of internal consistency. (D) The delusional-
depression composite score is not associated with the number of proautistic genotypes of the 8-SNP risk model in the discovery sample.
Data information: Error bars represent SEM.
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Figure 4. Association of autism severity readouts in the discovery and 3 independent replication samples with the number of proautistic genotypes in the
8-SNP risk model derived from the broader fragile X gene family.
A PAUSS (PANSS autism severity score) composition and item intercorrelation pattern in the GRAS sample of male schizophrenic individuals (discovery sample).
Cronbach’s alpha is presented as measure of internal consistency and also provided for the male replication samples I and II.
B Association of PAUSS with the number of proautistic genotypes of the 8-SNP risk model in the discovery sample; mean  SEM.
C PAUSS comparison of extreme groups with high and low numbers of accumulated proautistic genotypes in the discovery sample; binary logistic regression analysis
with non-z-standardized PAUSS as dependent variable; mean  SEM.
D PAUSS comparison of extreme groups with high and low numbers of accumulated proautistic genotypes in replication sample I of male schizophrenia patients;
binary logistic regression analysis; mean  SEM.
E PAUSS comparison of extreme groups with high and low numbers of accumulated proautistic genotypes in replication sample II of male disease control patients;
Mann–Whitney U-test; mean  SEM.
F The highly significant correlation of PAUSS and social support underlines the validity of social support as an autism proxy phenotype; mean  SEM.
G Comparison of the extreme groups with high and low numbers of accumulated proautistic genotypes for the autism proxy phenotype social support in the discovery
sample; binary logistic regression analysis; mean  SEM.
H Comparison of the extreme groups with high and low numbers of accumulated proautistic genotypes for the autism proxy phenotype social support in the male
replication sample III from general population; binary logistic regression analysis; mean  SEM. For all replications, P-values for one-sided tests are shown.
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mouse (Hatton et al, 2006; Dahlhaus & El-Husseini, 2010; Heitzer
et al, 2013).
We directly replicated the association of increasing genetic risk in
the 8-SNP accumulation model with increasing scores of PAUSS and
its sub-items in schizophrenic subjects (replication sample I) and
otherwise psychiatrically ill patients (replication sample II), even
though in the latter sample on a much lower level of symptom
severity (PAUSS) compared to the schizophrenia discovery and repli-
cation sample I. This fact is likely related to the disease spectrum
included in replication II, mainly consisting of affective disorders
and drug addiction. In these conditions, much less pronounced autis-
tic phenotypes would be expected, even considering the general
continuum of autistic traits in humans (Ka¨stner et al, 2015). Finally,
in line with the strong associations of the 8-SNP model obtained here
with social withdrawal as key feature of ASD, we were able to
demonstrate that an accumulation of ≥ 5.5 proautistic genotypes,
compared to ≤ 2.5 in a general population sample, is associated with
less self-reported social support. These findings further underline the
view that autistic traits can be found across different diagnostic
groups and even among individuals of the general population as a
phenotypic continuum and not just as a dichotomous category
(present/ absent).
Since 3 out of the 4 genes in the broader fragile X gene family are
putative targets of miR-181 species, we speculate that this
microRNA family may play an important role as an “umbrella
regulator” of ASD-relevant genes. The term “umbrella regulator” is
used here to describe a potential regulatory principle that is
common to different independent genes (which are even located on
Table 2. Hardy–Weinberg statistics and case–control analysis for
male patients with schizophrenia and healthy controls (GRAS).
(A)
Gene SNP
Test for HWE deviation
P-value total P-value controls P-value cases
FXR1 rs6763069 0.132 0.933 0.038
FXR1 rs2601 0.757 0.593 0.911
FXR2 rs34416693 0.116 0.358 0.653
FXR2 rs62059833 0.089 0.015 0.924
(B)








T 412 (58.3) 455 (62.7)
0.091
C 294 (41.7) 271 (37.3)
FXR1 rs6763069 0.325
AA 331 (47.4) 319 (44.5)
0.872AT 282 (40.3) 317 (44.3)
TT 86 (12.3) 80 (11.2)
FXR1 rs2601 0.212
AA 435 (61.7) 438 (60.2)
0.428AG 237 (33.6) 257 (35.3)
GG 33 (4.7) 33 (4.5)
FXR2 rs34416693 0.302
GG 342 (49.3) 368 (50.8)
0.280GA 287 (41.3) 304 (42.0)
AA 65 (9.4) 52 (7.2)
FXR2 rs62059833 0.278
CC 368 (53.0) 388 (53.6)
0.307CT 274 (39.5) 301 (41.6)
TT 52 (7.5) 35 (4.8)
FMR2 rs241084 0.272
A 514 (73.6) 544 (75.6)
0.393
G 185 (26.5) 176 (24.4)
FMR2 rs17318323 0.069
A 660 (93.2) 687 (94.1)
0.505
G 48 (6.8) 43 (5.9)
FMR2 rs6641482 0.112
A 629 (88.7) 648 (88.9)
0.887
G 80 (11.3) 81 (11.1)
(A) Test for deviation from Hardy–Weinberg equilibrium (HWE) in male
schizophrenic individuals (GRAS) and male healthy controls for non-X-
chromosomal SNP genotypes; significance level after correction for multiple
testing P < 0.013. (B) No significant differences in genotype frequencies in
case–control comparison of male schizophrenic patients (GRAS) with healthy
controls.
Table 3. Comparison of extreme groups with high and low numbers
of accumulated proautistic genotypes in the male GRAS sample











Autism-relevant measures (mean  SD)
Social withdrawal 2.10  1.22 3.10  1.67 Z = 3.71
P = 0.0002




2.53  1.07 3.16  1.38 Z = 2.80
P = 0.005








2.58  1.59 2.96  1.62 Z = 1.45
P = 0.146
PAUSSb 0.22  0.52 0.21  0.74 Z = 3.69
P = 0.0002
Control variables (mean  SD)
FMR1 repeat length 29.33  4.79 28.90  4.63 Z = 1.44
P = 0.151
FMR2 repeat length 17.41  3.10 17.89  3.72 Z = 0.41
P = 0.681
Age 36.97  10.79 38.74  14.01 Z = 0.69
P = 0.488




0.07  0.84 0.08  1.02 T = 0.44
P = 0.661
CNIc 0.06  1.06 0.14  0.95 T = 0.58
P = 0.562
Statistically significant P-values are set in boldface (Bonferroni-corrected
significance threshold: P < 0.007).
Mean  SD presented. For statistical analysis, Mann–Whitney U-test or
t-test for normally distributed variables was used. PANSS, positive and
negative syndrome scale; CNI, Cambridge Neurological Inventory.
aBecause of missing data, sample sizes vary.
bZ-standardized score.
cCorrected for age and chlorpromazine equivalents (standardized residual
after linear regression).
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different chromosomes) that all carry seed sequences of the miR-181
species. This microRNA family might therefore influence their
expression in the sense of an overarching regulatory mechanism. A
principle risk constellation may be given if miR-181 binding is
reduced (as in the 30UTR SNP rs2601 AA), or if miR-181 levels are
decreased (expression diminished or consumption/degradation
increased), together resulting as net effect in less efficient downreg-
ulation of target genes (the latter refers to the remaining 7 SNPs of
the model where high risk was associated with reduction of total
miR-181).
The miR-181 family members identified in our pilot approach
toward mechanistic insight are strongly brain-expressed. These
multiple regulators have been previously associated with neuro-
development, learning and memory function, glutamate signaling,
and neuroinflammation, and even some preliminary hints were
reported regarding autism, for example (Hutchison et al, 2013;
Mundalil Vasu et al, 2014). Further experimental in vivo work
using animal models will be needed to understand cause and
consequence of their regulation and their contribution to autistic
phenotypes.
To conclude, the present PGAS work provides first evidence that
a particular constellation of common genetic variants in the
“broader fragile X gene family” contributes to autistic phenotypes.
Even though still preliminary, the potential coordinator role of the
miR-181 family seems highly interesting and worth pursuing,
perhaps even with respect to future ASD treatment approaches.
Materials and Methods
Subjects
Discovery sample (schizophrenia patients of the GRAS cohort)
The Go¨ttingen Research Association for Schizophrenia (GRAS)
data collection has been established over the last 10 years and
consists of > 1,200 deep phenotyped patients, diagnosed with


















versus N = 57–68)a
P = 0.0002 P = 0.020 P = 0.002 P = 0.0002 P = 0.146 P = 0.003 P = 0.278 P = 0.003 P = 0.001
SNP taken out of the 8-SNP accumulation modela
rs25699 (FMR1)
(N = 64 versus
N = 11)b
P = 0.203 P = 0.490 P = 0.766 P = 0.310 P = 0.424 P = 0.114 P = 0.039# P = 0.089 P = 0.611
rs6763069 (FXR1)
(N = 48 versus
N = 24–26)
P = 0.195 P = 0.465 P = 0.135 P = 0.181 P = 0.455 P = 0.047 P = 0.242 P = 0.249 P = 0.120
rs2601 (FXR1)
(N = 107 versus
N = 10)
P = 0.595 P = 0.594 P = 0.709 P = 0.358 P = 0.899 P = 0.131 P = 0.239 P = 0.520 P = 0.955
rs34416693 (FXR2)
(N = 106 versus
N = 18)
P = 0.800 P = 0.766 P = 0.385 P = 0.376 P = 0.625 P = 0.032 P = 0.403 P = 0.325 P = 0.750
rs62059833 (FXR2)
(N = 110 versus
N = 16)
P = 0.075 P = 0.342 P = 0.291 P = 0.038 P = 0.306 P = 0.007 P = 0.529 P = 0.610 P = 0.528
rs241084 (FMR2)
(N = 95 versus
N = 10)
P = 0.226 P = 0.875 P = 0.986 P = 0.067 P = 0.902 P = 0.529 P = 0.187# P = 0.122 P = 0.524
rs17318323 (FMR2)
(N = 31 versus
N = 49)
P = 0.008 P = 0.039 P = 0.077 P = 0.026 P = 0.230 P = 0.419 P = 0.127# P = 0.048 P = 0.005
rs6641482 (FMR2)
(N = 38 versus
N = 48)
P = 0.118 P = 0.089 P = 0.072 P = 0.119 P = 0.882 P = 0.259 P = 0.955 P = 0.144 P = 0.020
P-values ≤ 0.05 in the 8-SNP accumulation model are set in boldface.
aIndividuals with 1.5–2.5 proautistic genotypes were compared to individuals with 5.5–6.5 proautistic genotypes by Mann–Whitney U-test.
bN numbers refer to the extreme groups (1.5–2.5 compared to 5.5–6.5 proautistic genotypes).
#P-values improve upon exclusion of the respective SNP only for 3 SNPs regarding stereotyped thinking; for all other SNPs and variables, P-values worsen upon
exclusion of the respective SNP.
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schizophrenia or schizoaffective disorder according to DSM-IV-TR
criteria (American Psychiatric Association, 2000), recruited across
23 collaborating centers across Germany (Begemann et al, 2010;
Ribbe et al, 2010). The study complies with the Helsinki
Declaration and was approved by the Ethics Committee of the
Georg-August-University (Go¨ttingen, Germany) as well as all
participating centers. All patients and/or their authorized legal
representatives gave written informed consent. The present study
focused on males only (N = 692 with complete data of a total of
N = 739) since the male gender is more commonly affected by both,
ASD and schizophrenia (Elsabbagh et al, 2012). Moreover, 2 of the
genes included in the accumulation model are X-chromosomal. The
average age of the discovery sample was 37.29  12.06 years (range
17–78).
Healthy control sample (GRAS healthy blood donors)
Healthy male controls for genetic case–control analysis were
voluntary blood donors (N = 783; mean age 38.41  13.29 years;
range 18–69) from Department of Transfusion Medicine of the
George-August-University (Go¨ttingen, Germany) which widely fulfill
health criteria, assessed by predonation screening (Begemann et al,
2010).





































5.5 – 6.5 





rs2601 (G) FMR1 FMR2 (1) FMR2 (2) FMR2 (3) FMR2 (4) FMR2 (5)
hsa-miR-181a-5p nd –3.84 nd –0.54 nd –0.16 –4.37 –11.76
hsa-miR-181b-5p nd –9.90 –0.19 nd –2.95 nd –3.07 –10.06
hsa-miR-181c-5p nd –4.44 nd –1.14 nd nd –7.07 –7.36










hsa-miR-181a-5p         3’-UGAGUGGCUGUCGCAACUUACAA- 5’ Chr1:198859123-198859129
Chr9:124692495-124692501 
hsa-miR-181b-5p         3’-UGGGUGGCUGUCGUUACUUACAA- 5’ Chr1:198858940-
-
198858946 
Chr9:124693740 124693746  
hsa-miR-181c-5p         3’- UGAGUGGCUGUCCAACUUACAA- 5’ Chr19:13874739-13874745
hsa-miR-181d-5p         3’-UGGGUGGCUGUUGUUACUUACAA- 5’ Chr19:13874925-13874931 
FXR1-rs2601(A)          5’- …UAGAGCCCUCACAUGGAUAACAUU… -3’ Chr3:180982357-180982361
FXR1-rs2601(G)          5’- …UAGAGCCCUCACAUGGAUGACAUU… -3’ Chr3:180982357-180982362
FMR1   5’- …GUUAUUUAUUCUGGGAAUGUAUAG… -3’ ChrX:147950394-147950399
FMR2 (1)   5’- …GAAACUAGACAUUAGAAUGUUGAG… -3’ ChrX:148993575-148993580
FMR2 (2)   5’- …ACACAGUAUCAAAUGAAUGGGUCA… -3’ ChrX:148995034-148995039
FMR2 (3)   5’- …AUGAAUCAAUGUGUGAAUGUAGAA… -3’ ChrX:148996642-148996647
FMR2 (4) 5’- …CUGUAUCCAUGGUUGAAUGUUAGC… -3’ ChrX:148997522-148997528
FMR2 (5) 5’- …GUCUUUGAUAAAAUGAAUGUCAGU… -3’ ChrX:148998068-148998074
FXR2 no seed match detectable Chr17
rs2601
nd, not detectable
Figure 5. Pilot experiments toward first mechanistic insight.
A FXR1 expression in PBMC of individuals carrying the rs2601 GG (low risk; N = 16) versus AA genotype (high risk; N = 27). Data represent mean  SEM.
B PBMC microRNA expression was normalized and data are plotted from all 4 miR-181-5p members (miR-181a, miR-181b, miR-181c, d miR-181-5p). The bottom and
top of the box are the first and third quartiles; the band inside the box is the median; the ends of the whiskers represent minimum and maximum values of the data.
C Sequence homology of all four human mature miR-181 species shown together with sequences in the broader fragile X gene family containing binding sites for the
miR-181 family (seed matches identified using Target Scan Human and SFOLD). The red letters specify seed sequences and seed matches, respectively. Chromosome
positions for each seed sequence and seed match are denoted (human genome assembly GRCh38/hg38).
D Denoted are ΔΔG values for binding of each of the miR-181 family members to different 30UTR positions. Positions were identified using Target Scan Human and
SFOLD and then processed using PITA algorithm to yield the denoted ΔΔG values. ΔΔG is an energetic score, and the more negative its value, the stronger is the
expected binding of the microRNA to the given site (Kertesz et al, 2007).
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Replication sample I (schizophrenia patients, Munich/Halle cohort)
To replicate in an independent schizophrenia sample, the pheno-
type–genotype associations found in GRAS patients, data from
male subjects (N = 626; mean age 35.49  11.22 years; range 18–67)
of the Munich/Halle collection, diagnosed with schizophrenia
according to DSM-IV-TR criteria (American Psychiatric Association,
2000), were analyzed (Van den Oord et al, 2006). Written informed
consent had been obtained from all subjects after detailed and
extensive description of the study, which was approved by the local
ethics committees and carried out according to the Declaration of
Helsinki.
Replication sample II (GRAS disease control cohort)
Replication sample II consists of 111 males (mean age
42.37  14.87 years; range 18–75) diagnosed with psychiatric
disorders other than schizophrenia (71.2% affective disorders,
15.3% substance use disorders, 13.5% others) according to DSM-IV-
TR (American Psychiatric Association 2000). All patients were origi-
nally recruited as part of the GRAS study but upon careful diagnosis
validation (review of psychiatric history, Structured Clinical Inter-
view for DSM-IV, SCID I) failed to fulfill DSM-IV-TR criteria for
schizophrenia or schizoaffective disorder.
Replication sample III (population-based cohort, SHIP)
Replication sample III comprises 2,005 male subjects (mean age
50.91  16.41 years; range = 20–80) from the baseline cohort of
the Study of Health in Pomerania (SHIP), conducted in North-East
Germany. SHIP investigates common risk factors and subclinical
disorders and manifests diseases in the general population (Vo¨lzke
et al, 2011). All participants gave written informed consent. The
survey and study methods were approved by the institutional
review boards of the University of Greifswald.
Phenotyping
Target phenotype: the PANSS autism severity score (PAUSS)
To capture autistic features, an autism severity score (PAUSS) was
calculated for the discovery sample and replication samples I and II
(Ka¨stner et al, 2015). It represents the mean of six items of the
negative and two items of the general subscale of the Positive and
Negative Syndrome Scale (PANSS) (Kay et al, 1987). For the replica-
tion sample III, the Instrumental Support Index (ISI, self-report) was
used as proxy phenotype indicating the quality of instrumental and
emotional support (Klein et al, 2012). The ability to establish and
maintain high-quality relationships is crucial for receiving social
support when needed. These skills are expected to be low in individ-
uals with ASD or with strong autistic phenotypes and should be
reflected by lower support. To cross-validate this proxy phenotype
in the discovery sample (GRAS), social support was operationalized
as the self-reported number of individuals a person can rely on in
case of emergency. For both measures of social support, higher
values represent higher social support, that is, lower autistic
features.
Further schizophrenia-relevant phenotypes
For the discovery sample, the severity of psychotic symptoms was
evaluated by the PANSS (Kay et al, 1987). The Cambridge Neuro-
logical Inventory (CNI) (Chen et al, 1995) was applied as a measure
of neurological functioning and a number of neuropsychological
tests were administered. As global measure of cognitive functioning,
a cognitive composite score, comprising reasoning (subtest 3, Leis-
tungspru¨fsystem, [LPS3]), executive function (Trail-Making Test,
part B [TMT-B], and verbal learning and memory (Verbal Learning
and Memory Test [VLMT]), was employed (Begemann et al, 2010).
As control phenotype, a delusional-depression composite score was
used, based on other GRAS database items (Fig 3C) (Ribbe et al,
2010).
Microsatellite analysis
For the discovery sample and the healthy control sample (GRAS),
2 polymorphic repeats in the 50UTR regions of FMR1 and FMR2
genes were amplified from genomic DNA by PCR. Primers for
CGG/CCG repeats at the FMR1/FMR2 genes were designed
according to published information (Fu et al, 1991; Santos et al,
2001).
FMR1: CGG repeat




Primer XE2: 50-GCCCTCCCGCCCAGCTAAAAGTGTCCGGG-30 (label-
ing FAM)
Primer 603: 50-CCTGTGAGTGTGTAAGTGTGTGATGCTGCCG-30
For each sample, the reaction mixture (21 ll) was prepared in
384 well plates, each containing 1 ll (50 ng) of human genomic
DNA, 10 ll QIAGEN Multiplex PCR Plus Kit (Qiagen, Hilden,
Germany), 6 ll Q-Solution (Qiagen) and 4 ll VIC- or FAM-labeled
forward primer and unlabeled reverse primer (190 nM final each).
The cycling program was carried out after a preheating step at
98°C for 5 min and included 35 cycles of: (1) denaturation at 98°C
for 45s, (2) annealing at 68°C for 2 min and (3) extension at 72°C
for 2 min, followed by a final extension step at 72°C for 20 min in
a DNA Thermal Cycler (PTC-200 MJ Research, Bio-Rad, Munich,
Germany). The amplicons were separated using size electrophoresis
on the ABI 3730 XL DNA Analyzer. Samples were diluted 1:50 with
0.3 mM EDTA and 4 ll was mixed with 6 ll LIZ-500 Size Standard
(Applied Biosystems, Foster City, CA, USA). Raw data were
processed using the Gene Mapper Software 4.0 (Applied Biosys-
tems). Overall, successfully genotyped markers amounted to 98.1%.
Genotyping
GRAS sample
The GRAS sample (discovery sample, replication sample II—disease
controls, and healthy controls) was genotyped using a semicustom
Axiom MyDesign Genotyping Array (Affymetrix, Santa Clara, CA,
USA), based on a CEU (Caucasian residents of European ancestry
from UT, USA) marker backbone including 518,722 SNPs, and a
custom marker set including 102,537 SNPs. Genotyping was
performed by Affymetrix on a GeneTitan platform. Several quality
control steps were applied (SNP call rate > 97%, Fisher’s linear
discriminant, heterozygous cluster strength offset, homozygote ratio
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offset) (Hammer et al, 2014; Stepniak et al, 2014). From the 739
GRAS males, 30 individuals had to be excluded from further analy-
sis due to relatedness, genotyping problems, and genetic population
outlier status (based on 10 principle components). Similarly, of the
783 healthy controls, 53 individuals had to be excluded from further
analysis for the same reasons.
Replication sample I
Replication sample I was genotyped using the iPLEX assay on the
MassARRAY MALDI-TOF mass spectrometer as described (Oeth
et al, 2009). Allele-specific extension products were identified and
genotypes allocated by Typer 3.4 Software (Sequenom, San Diego,
CA, USA). All applied quality criteria were met (individual call rate
> 80%, SNP call rate > 99%, identity of genotyped CEU Trios
[Coriell Institute for Medical Research, Camden, NJ] with HapMap
database > 99%).
Replication sample III—SHIP-0
Replication sample III, SHIP-0, was genotyped using the Affymetrix
Genome-Wide Human SNP Array 6.0. Hybridization of genomic
DNA was done in accordance with the manufacturer’s standard
recommendations. The overall genotyping efficiency was 98.6%.
Imputation of genotypes in the SHIP cohort was performed with the
software IMPUTE v0.5.0 against the 1,000 Genomes (phase 1v3)
reference panel using 869,224 genotyped SNPs (Vo¨lzke et al, 2011).
Marker selection
From the broader fragile X gene family (FMR1, FXR1, FXR2, FMR2),
markers were in a first step preselected according to the following
selection criteria: (i) SNPs with potentially functional significance
(located in promoter region, 30UTR or coding sequence) to later
facilitate potential mechanistic insight; (ii) SNPs with reasonable
minor allele frequency (MAF ≥ 0.2) to allow for statistical analyses
in our discovery sample; and (iii) SNPs not in high linkage disequi-
librium (LD) with another selected SNP (r² < 0.8) to exclude redun-
dant information (priority was given here to the SNPs fulfilling the
aforementioned criteria of functionality and MAF). This preselection
yielded a total of 13 SNPs (Fig 2). In a second step, a phenotype-
based genetic association study (PGAS) approach using the PAUSS
(Ka¨stner et al, 2015) was performed individually on all 13 SNPs.
SNPs with a tendency of one genotype being associated with an
autistic phenotype went into the final accumulation model of 8 SNPs
(standard operating procedure, SOP, explained in Figs 2 and 3). Not
more than 3 SNPs per gene were ultimately selected to avoid over-
representation of one gene (Figs 1A, 2 and 3).
Isolation of peripheral blood mononuclear cells (PBMC)
Morning blood samples were obtained via phlebotomy into CPDA
vials (Citrate Phosphate Dextrose Adenine, Sarstedt, Germany).
PBMC were isolated applying the standard Ficoll-Paque Plus isola-
tion procedure (GE Healthcare, Munich, Germany).
Reverse transcription and real-time PCR
Total RNA was extracted with RNAeasy kit (Qiagen, Hilden,
Germany) from PBMC and cDNA synthesis carried out via
SuperscriptIII kit (Invitrogen, Karlsruhe, Germany). FXR1 and
GAPDH cDNA was detected in LightCycler480 via SYBR green
(Roche, Diagnostics GmbH, Mannheim, Germany) using specific
primers:





RNA was extracted from PBMC using TRI Reagent, chloroform, and
isopropyl alcohol. Library preparation and cluster generation was
performed according to the Illumina standard protocols (TruSeq,
Illumina, San Diego, CA, USA). Libraries were quality-controlled
and quantified using a Nanodrop 2000 (Thermo Scientific, Darm-
stadt, Germany), Agilent 2100 Bioanalyzer (Agilent Technologies,
Waldbronn, Germany) and Qubit (Life Technologies, Darmstadt,
Germany). Base calling from raw images and file conversion to fastq
files were achieved by Illumina pipeline scripts. 30 adapters were
trimmed and filtered for reads with the minimum length of 15
nucleotides using cutadapt (Martin, 2011) prior to the mapping.
Reads were then mapped to a reference genome created from the
mature microRNA sequences in human genome using RNA-STAR
(Dobin et al, 2013). No mismatches for reads < 20 b were allowed,
1 mismatch was allowed for reads between 20 b and 39 b, and 2
mismatches for reads between 40 b and 59 b. Reads were mapped
in non-splice-junction-aware mode. Remaining unmapped reads
were then mapped to the human genome (GRC37), and only high-
quality reads (MAPQ ≥ 30) were considered. In order to obtain the
total number of uniquely mapped reads for each sample, high-
quality uniquely mapped reads from mature microRNA and human
genome (GRC37) were combined. The normalized read counts were
then obtained by dividing the read’s count by the total number of
uniquely mapped reads for the samples, respectively. Since RNA
sequencing is not biased by probe design, we were able to quantify
miR-181 levels using the normalized read counts for miR-181a, miR-
181b, miR-181c, and miR-181d-5p detected in high- and low-risk
groups for statistical analysis.
FMRP determination
PBMC were resuspended in lysis buffer containing 1% NP-40 in PBS
(140 mM NaCl, 2.7 mM KCl, 3.2 mM Na2HPO4, 1.5 mM KH2PO4,
pH 7.4) and incubated for 10 min on ice. Lysates were cleared by
centrifugation at 11,200 g for 10 min at 4°C and protein concentra-
tions determined by Bradford colorimetry (Bio-Rad City, CA, USA).
Extracts containing 60 lg total protein were separated by SDS–
PAGE and transferred to a polyvinylidene difluoride membrane
(Millipore, Schwalbach, Germany) by Western blotting. The
membrane was blocked with 5% w/v nonfat milk in TBT (150 mM
NaCl, 6 mM Tris base, 15 mM Tris–HCl pH 7.5, 0.5% Tween-20) at
room temperature for 40 min and incubated with the primary anti-
bodies against FMRP (1:200, Millipore MAB2160) and beta-actin
(house keeper; 1:1,000, Sigma Aldrich A5316, Seelze, Germany) at
4°C for 12 h. After washing with TBT, the membrane was incubated
with a horseradish peroxidase-conjugated anti-mouse antibody
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(1:5,000, Sigma Aldrich A4416) for 2 h at room temperature. The
blot was developed with the enhanced chemiluminescence (ECL)
system and signals were quantified (relative units) using ImageJ
software (Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997–2014).
Statistical analysis
Mann–Whitney U-test or binary logistic regression was used
for group comparisons or t-test in case of normally distributed
dependent variables and no lack of homogeneity of variances.
Spearman rank correlation coefficient was used to assess the
strength of association between 2 non-parametric variables.
Cronbach’s alpha was calculated as a measure of internal consis-
tency. For exclusion of statistical outliers, the Grubbs’ test was used.
Statistical analyses were performed with SPSS for windows version
17.0 (IBM-Deutschland GmbH, Munich, Germany) or with STATA/
MP software, version 13 (StataCorp LP, College Station, TX).
Case–control analysis of SNP genotypes as well as test for deviation
from Hardy–Weinberg equilibrium was performed using PLINK
1.07 (Purcell et al, 2007).
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